Roth Capital maintains its Buy rating and $30 price target on Keryx Biopharmaceuticals (Nasdaq: KERX) folloing Q4/FY13 results issued Thursday ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE